Biltmore Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Biltmore Capital Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$219K	Buy	+1,692	New	+$197K	0.04%	142

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Biltmore Capital Advisors's EW Position: Q4 2021 in Review

Biltmore Capital Advisors opened a new position in Edwards Lifesciences (EW) in Q4 2021: 1,692 shares worth $219K. The stake represents 0.04% of the portfolio and ranks #142 among its holdings.

1,320 funds tracked by Wall St. Rank hold EW as of Q4 2021.

Biltmore Capital Advisors held 1,692 shares of Edwards Lifesciences worth $219K as of Q4 2021.
Edwards Lifesciences was a new Biltmore Capital Advisors position in Q4 2021.
Edwards Lifesciences made up 0.04% of Biltmore Capital Advisors's portfolio in Q4 2021, its #142 holding.
1,320 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2021.

Based on Biltmore Capital Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.